AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
A 15-yr-old boy with stage IA nodular, sclerosing Hodgkin's disease was offered multiagent chemotherapy. In April, 1998, despite lengthy discussion with the treatment team, the patient, with the approval of his mother, elected to use Matol Bioimmune OSF Plus. According to the manufacturer's promotional literature, the product would "create a synergistic effect on the immune system, resulting in the elevation of natural killer (NK) cell activity." Case reports provided by Matol Botanical International indicate that the compound has beneficial effects on a …